Published in BMC Cancer on March 08, 2010
Tocotrienols, the vitamin E of the 21st century: its potential against cancer and other chronic diseases. Biochem Pharmacol (2010) 1.82
{Gamma}-tocotrienol inhibits pancreatic tumors and sensitizes them to gemcitabine treatment by modulating the inflammatory microenvironment. Cancer Res (2010) 1.17
Efficacy and mechanism of action of the tyrosine kinase inhibitors gefitinib, lapatinib and neratinib in the treatment of HER2-positive breast cancer: preclinical and clinical evidence. Am J Cancer Res (2015) 0.88
Mechanisms Mediating the Synergistic Anticancer Effects of Combined γ-Tocotrienol and Celecoxib Treatment. J Bioanal Biomed (2011) 0.80
Effect of PEG surface conformation on anticancer activity and blood circulation of nanoemulsions loaded with tocotrienol-rich fraction of palm oil. AAPS J (2013) 0.77
Synergistic Antiproliferative Effects of Combined γ -Tocotrienol and PPAR γ Antagonist Treatment Are Mediated through PPAR γ -Independent Mechanisms in Breast Cancer Cells. PPAR Res (2014) 0.76
Mechanisms Mediating the Effects of γ-Tocotrienol When Used in Combination with PPARγ Agonists or Antagonists on MCF-7 and MDA-MB-231 Breast Cancer Cells. Int J Breast Cancer (2013) 0.76
Targeting met mediated epithelial-mesenchymal transition in the treatment of breast cancer. Clin Transl Med (2014) 0.76
ErbB4 as a potential molecular target in the treatment of esophageal squamous cell cancers. ScientificWorldJournal (2014) 0.76
Synergistic Anticancer Effect of Tocotrienol Combined with Chemotherapeutic Agents or Dietary Components: A Review. Int J Mol Sci (2016) 0.75
In vitro evaluation of combination of EGCG and Erlotinib with classical chemotherapeutics on JAR cells. In Vitro Cell Dev Biol Anim (2017) 0.75
Electrophoretic transfer of proteins from polyacrylamide gels to nitrocellulose sheets: procedure and some applications. Proc Natl Acad Sci U S A (1979) 365.71
Untangling the ErbB signalling network. Nat Rev Mol Cell Biol (2001) 28.05
The ErbB signaling network: receptor heterodimerization in development and cancer. EMBO J (2000) 9.51
Escape from HER-family tyrosine kinase inhibitor therapy by the kinase-inactive HER3. Nature (2007) 6.56
The ErbB2/ErbB3 heterodimer functions as an oncogenic unit: ErbB2 requires ErbB3 to drive breast tumor cell proliferation. Proc Natl Acad Sci U S A (2003) 6.37
Mechanisms of disease: understanding resistance to HER2-targeted therapy in human breast cancer. Nat Clin Pract Oncol (2006) 4.91
gamma -Secretase cleavage and nuclear localization of ErbB-4 receptor tyrosine kinase. Science (2001) 4.90
BIM mediates EGFR tyrosine kinase inhibitor-induced apoptosis in lung cancers with oncogenic EGFR mutations. PLoS Med (2007) 4.50
Expression of the HER1-4 family of receptor tyrosine kinases in breast cancer. J Pathol (2003) 4.05
Coexpression of erbB2 and erbB3 proteins reconstitutes a high affinity receptor for heregulin. J Biol Chem (1994) 3.46
ErbB-2 is a common auxiliary subunit of NDF and EGF receptors: implications for breast cancer. EMBO J (1996) 3.22
A neu acquaintance for erbB3 and erbB4: a role for receptor heterodimerization in growth signaling. Cell (1994) 2.64
Biology of HER2 and its importance in breast cancer. Oncology (2001) 2.54
Cross-talk between epidermal growth factor receptor and c-Met signal pathways in transformed cells. J Biol Chem (2000) 2.46
Resistance to gefitinib in PTEN-null HER-overexpressing tumor cells can be overcome through restoration of PTEN function or pharmacologic modulation of constitutive phosphatidylinositol 3'-kinase/Akt pathway signaling. Clin Cancer Res (2003) 2.33
Heterodimerization of insulin-like growth factor receptor/epidermal growth factor receptor and induction of survivin expression counteract the antitumor action of erlotinib. Cancer Res (2006) 2.31
c-erbB-3: a nuclear protein in mammary epithelial cells. J Cell Biol (2002) 2.27
Cooperative inhibitory effect of ZD1839 (Iressa) in combination with trastuzumab (Herceptin) on human breast cancer cell growth. Ann Oncol (2002) 2.14
Chemistry and biology of vitamin E. Mol Nutr Food Res (2005) 1.59
The ErbB receptors and their ligands in cancer: an overview. Curr Drug Targets (2005) 1.59
Signal transduction by epidermal growth factor and heregulin via the kinase-deficient ErbB3 protein. Biochem J (1998) 1.57
c-erbB3 and c-erbB4 expression is a feature of the endocrine responsive phenotype in clinical breast cancer. Oncogene (1998) 1.30
Pharmacokinetics and bioavailability of alpha-, gamma- and delta-tocotrienols under different food status. J Pharm Pharmacol (2001) 1.28
Lowering of serum cholesterol in hypercholesterolemic humans by tocotrienols (palmvitee). Am J Clin Nutr (1991) 1.28
Targeting ErbB receptor signaling: a pan-ErbB approach to cancer. Mol Cancer Ther (2004) 1.25
Additive antitumour effect of the epidermal growth factor receptor tyrosine kinase inhibitor gefitinib (Iressa, ZD1839) and the antioestrogen fulvestrant (Faslodex, ICI 182,780) in breast cancer cells. Br J Cancer (2004) 1.21
Differential nuclear localization and kinase activity of alternative ErbB4 intracellular domains. Oncogene (2007) 1.18
Tocotrienols inhibit the growth of human breast cancer cells irrespective of estrogen receptor status. Lipids (1998) 1.14
Antiproliferative and apoptotic effects of tocopherols and tocotrienols on preneoplastic and neoplastic mouse mammary epithelial cells. Proc Soc Exp Biol Med (2000) 1.09
Antiproliferative and apoptotic effects of tocopherols and tocotrienols on normal mouse mammary epithelial cells. Lipids (2000) 1.07
Retracted Erlotinib induces mitochondrial-mediated apoptosis in human H3255 non-small-cell lung cancer cells with epidermal growth factor receptorL858R mutation through mitochondrial oxidative phosphorylation-dependent activation of BAX and BAK. Mol Pharmacol (2008) 1.06
Selection and characterization in culture of mammary tumor cells with distinctive growth properties in vivo. Cancer Res (1980) 1.02
Novel therapeutic strategies targeting the epidermal growth factor receptor (EGFR) family and its downstream effectors in breast cancer. Ann Oncol (2003) 1.01
gamma-Tocotrienol inhibits ErbB3-dependent PI3K/Akt mitogenic signalling in neoplastic mammary epithelial cells. Cell Prolif (2006) 1.01
New cell line. Epithelial cell line and subline established from premalignant mouse mammary tissue. In Vitro (1979) 0.98
Vitamin E and apoptosis. Vitam Horm (2007) 0.97
Mechanisms mediating the antiproliferative and apoptotic effects of vitamin E in mammary cancer cells. Front Biosci (2005) 0.94
Tocotrienol-induced caspase-8 activation is unrelated to death receptor apoptotic signaling in neoplastic mammary epithelial cells. Exp Biol Med (Maywood) (2004) 0.91
Dose-response impact of various tocotrienols on serum lipid parameters in 5-week-old female chickens. Lipids (2006) 0.90
Synergistic antiproliferative effects of gamma-tocotrienol and statin treatment on mammary tumor cells. Lipids (2007) 0.90
Fatty acid modulation of epidermal growth factor-induced mouse mammary epithelial cell proliferation in vitro. Exp Cell Res (1994) 0.86
Trastuzumab therapy vs tetracycline controlled ERBB2 downregulation: influence on tumour development in an ERBB2-dependent mouse tumour model. Br J Cancer (2008) 0.84
Tocotrienol-induced cytotoxicity is unrelated to mitochondrial stress apoptotic signaling in neoplastic mammary epithelial cells. Biochem Cell Biol (2005) 0.82
Small molecule epidermal growth factor receptor tyrosine kinase inhibitors: an overview. J Chemother (2004) 0.78
A new mixed-backbone oligonucleotide against glucosylceramide synthase sensitizes multidrug-resistant tumors to apoptosis. PLoS One (2009) 1.11
Gamma-tocotrienol inhibits neoplastic mammary epithelial cell proliferation by decreasing Akt and nuclear factor kappaB activity. Exp Biol Med (Maywood) (2005) 1.06
(-)-Oleocanthal as a c-Met inhibitor for the control of metastatic breast and prostate cancers. Planta Med (2011) 0.97
Endoplasmic reticulum stress mediates gamma-tocotrienol-induced apoptosis in mammary tumor cells. Apoptosis (2009) 0.91
Role of caspase-8 activation in mediating vitamin E-induced apoptosis in murine mammary cancer cells. Nutr Cancer (2003) 0.91
Tocotrienol-induced caspase-8 activation is unrelated to death receptor apoptotic signaling in neoplastic mammary epithelial cells. Exp Biol Med (Maywood) (2004) 0.91
Synergistic antiproliferative effects of gamma-tocotrienol and statin treatment on mammary tumor cells. Lipids (2007) 0.90
Synergistic anticancer effects of combined gamma-tocotrienol and celecoxib treatment are associated with suppression in Akt and NFkappaB signaling. Biomed Pharmacother (2009) 0.90
Combined gamma-tocotrienol and erlotinib/gefitinib treatment suppresses Stat and Akt signaling in murine mammary tumor cells. Anticancer Res (2010) 0.86
Comparison of the intestinal absorption and bioavailability of γ-tocotrienol and α-tocopherol: in vitro, in situ and in vivo studies. Biopharm Drug Dispos (2012) 0.85
Development and validation of a reversed-phase HPLC method for the determination of γ-tocotrienol in rat and human plasma. Biomed Chromatogr (2010) 0.84
Thyroid hormone, glucocorticoids, and prolactin at the nexus of physiology, reproduction, and toxicology. Toxicol Appl Pharmacol (2004) 0.83
Molecular interaction and localization of tocotrienol-rich fraction (TRF) within the matrices of lipid nanoparticles: evidence studies by Differential Scanning Calorimetry (DSC) and Proton Nuclear Magnetic Resonance spectroscopy ((1)H NMR). Colloids Surf B Biointerfaces (2010) 0.83
Rational design and semisynthesis of betulinic acid analogues as potent topoisomerase inhibitors. J Nat Prod (2009) 0.82
Tocotrienol-induced cytotoxicity is unrelated to mitochondrial stress apoptotic signaling in neoplastic mammary epithelial cells. Biochem Cell Biol (2005) 0.82
Bioactive rearranged and halogenated semisynthetic derivatives of the marine natural product sarcophine. J Nat Prod (2004) 0.82
Intestinal absorption of gamma-tocotrienol is mediated by Niemann-Pick C1-like 1: in situ rat intestinal perfusion studies. Drug Metab Dispos (2010) 0.82
Preparation, characterization, and anticancer effects of simvastatin-tocotrienol lipid nanoparticles. Int J Pharm (2010) 0.82
Molecular modelling and multisimplex optimization of tocotrienol-rich self emulsified drug delivery systems. Int J Pharm (2012) 0.82
Sesamin synergistically potentiates the anticancer effects of γ-tocotrienol in mammary cancer cell lines. Fitoterapia (2012) 0.81
Suppression in mevalonate synthesis mediates antitumor effects of combined statin and gamma-tocotrienol treatment. Lipids (2009) 0.81
Nonlinear absorption kinetics of self-emulsifying drug delivery systems (SEDDS) containing tocotrienols as lipophilic molecules: in vivo and in vitro studies. AAPS J (2013) 0.81
Induction of expression and functional activity of P-glycoprotein efflux transporter by bioactive plant natural products. Food Chem Toxicol (2011) 0.81
Antiproliferative triterpenes from Melaleuca ericifolia. J Nat Prod (2008) 0.80
Redox-silent tocotrienol esters as breast cancer proliferation and migration inhibitors. Bioorg Med Chem (2010) 0.80
Mechanisms Mediating the Synergistic Anticancer Effects of Combined γ-Tocotrienol and Celecoxib Treatment. J Bioanal Biomed (2011) 0.80
Stability and in vitro antiproliferative activity of bioactive "Vitamin E" fortified parenteral lipid emulsions. Colloids Surf B Biointerfaces (2012) 0.80
Sinulodurins A and B, antiproliferative and anti-invasive diterpenes from the soft coral Sinularia dura. J Nat Prod (2008) 0.80
"Vitamin E" fortified parenteral lipid emulsions: Plackett-Burman screening of primary process and composition parameters. Drug Dev Ind Pharm (2012) 0.80
Combined treatment of gamma-tocotrienol with statins induce mammary tumor cell cycle arrest in G1. Exp Biol Med (Maywood) (2009) 0.80
Enhanced solubility and oral bioavailability of γ-tocotrienol using a self-emulsifying drug delivery system (SEDDS). Lipids (2014) 0.80
Entrapment into nanoemulsions potentiates the anticancer activity of tocotrienols against the highly malignant (+SA) mouse mammary epithelial cells. J Nanosci Nanotechnol (2014) 0.79
Mechanisms mediating the synergistic anticancer effects of combined γ-tocotrienol and sesamin treatment. Planta Med (2012) 0.79
Tocotrienol combination therapy results in synergistic anticancer response. Front Biosci (Landmark Ed) (2011) 0.78
Enhancement of intestinal permeability utilizing solid lipid nanoparticles increases γ-tocotrienol oral bioavailability. Lipids (2012) 0.78
Semisynthetic and biotransformation studies of (1S,2E,4S,6R,7E,11E)-2,7,11-cembratriene-4,6-diol. J Nat Prod (2008) 0.77
Statistical measures of transcriptional diversity capture genomic heterogeneity of cancer. BMC Genomics (2014) 0.77
Design and preliminary structure-activity relationship of redox-silent semisynthetic tocotrienol analogues as inhibitors for breast cancer proliferation and invasion. Bioorg Med Chem (2009) 0.76
Repeated cocaine decreases the avoidance response to a novel aversive stimulus in rats. Psychopharmacology (Berl) (2002) 0.76
Mechanisms Mediating the Effects of γ-Tocotrienol When Used in Combination with PPARγ Agonists or Antagonists on MCF-7 and MDA-MB-231 Breast Cancer Cells. Int J Breast Cancer (2013) 0.76
Biocatalytic and semisynthetic studies of the anticancer tobacco cembranoids. Expert Opin Investig Drugs (2007) 0.76
γ-Tocotrienol-induced autophagy in malignant mammary cancer cells. Exp Biol Med (Maywood) (2013) 0.76
Caudal hindbrain glucoprivation enhances gamma-aminobutyric acid release in discrete septopreoptic structures in the steroid-primed ovariectomized rat brain: role of mu opioid receptors. Neuroendocrinology (2004) 0.76
Optimization of tocotrienols as antiproliferative and antimigratory leads. Eur J Med Chem (2012) 0.76
Biocatalysis of the anticancer sipholane triterpenoids. Planta Med (2007) 0.75
Design and pharmacophore modeling of biaryl methyl eugenol analogs as breast cancer invasion inhibitors. Bioorg Med Chem (2009) 0.75
Synthesis of fluorescent analogues of the anticancer natural products 4-hydroxyphenylmethylene hydantoin and delta-tocotrienol. Nat Prod Commun (2010) 0.75
Effect of lipid viscosity and high-pressure homogenization on the physical stability of "Vitamin E" enriched emulsion. Pharm Dev Technol (2014) 0.75